Abstract
Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder and is associated with structural grey matter differences in the brain. We investigated the genetic background of some of these brain differences in a sample of 899 adults and adolescents consisting of individuals with ADHD and healthy controls. Previous work in an overlapping sample identified three ADHD-related grey matter brain networks located in areas of the superior, middle, and inferior frontal gyrus as well as the cerebellar tonsil and culmen. We associated these brain networks with protein coding genes using a statistical stability selection approach. We identified ten genes, the most promising of which were NR3C2, TRHDE, SCFD1, GNAO1, and UNC5D. These genes are expressed in brain and linked to neuropsychiatric disorders including ADHD. With our results we aid in the growing understanding of the aetiology of ADHD from genes to brain to behaviour.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project has received funding from the European Union's Seventh Framework Programme for research, technological development and demonstration under grant agreement no 602805 - AGGRESSOTYPE. Additional support for this work was received from the European Community's Horizon 2020 Programme (H2020/2014 - 2020) under supported by the US. National Institutes of Health through the grant agreement no 728018 (Eat2beNICE). 1R01MH106655. The founder has no active role in this study. This work is part of the research programme Computing Time National Computing Facilities Processing Round pilots 2018 with project number 17666, which is (partly) financed by the Dutch Research Council (NWO). This work was carried out on the Dutch national e-infrastructure with the support of SURF Cooperative. This paper reflects only the authors' views, and the European Union is not liable for any use that may be made of the information contained therein.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the regional ethics committee (Centrale Commissie Mens-gebonden Onderzoek: CMO Regio Arnhem-Nijmegen; 2008/163; ABR: NL23894.091.08; Protocol number III.04.0403) and the medical ethical committee of the VU University Medical Center. Written informed consent was obtained from all participants.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data is available upon application though https://www.ru.nl/donders/research/research-facilities-projects/neuroimage/ and https://www.impactadhdgenomics.com/
https://www.ru.nl/donders/research/research-facilities-projects/neuroimage/